.
MergerLinks Header Logo

Announced

Nuance Pharma to acquire Sino Health.

Financials

Edit Data
Transaction Value-
Consideration TypeCash
Capital Owned-
Capital Bid For100%
EV/Sales-
EV/EBITDA-
Share Price Premium-
One Off Charge-

Tags

Edit

Friendly

pharmaceutical company

Pending

Pharmaceuticals

Acquisition

Domestic

Majority

Single Bidder

Private

China

Synopsis

Edit

Nuance Pharma, a Shanghai-headquartered specialty care focused biopharma company, agreed to acquire Sino Health, a medical service provider. Financial terms were not disclosed. "This is another important milestone for Nuance in the implementation of our 'Dual Wheel' strategy. While bringing together global innovative assets, we continuously put our efforts in commercialization of products in high value therapeutic area's across China. The acquisition not only enriches our portfolio, through expansion into the emergency care, but also strengthens the sales network and supply chain capabilities and the Company's commercial footprint. The deal also materially improves our working capital and cash flow whilst generating multiple synergies on the commercialization of assets across China. Under the current market volatility, the transaction will ensure that Nuance is well-positioned for existing and future needs for commercialization," Mark Gavin Lotter, Nuance CEO.

© COPYRIGHT 2024 MERGERLINKS LIMITED.

ALL RIGHTS RESERVED.

15 BONHILL STREET, LONDON, EC2A 4DN, UNITED KINGDOM.

CONTACT US